Palmitoylethanolamide (PEA) for ALS
Also known as: PEA, Normast, Levagen
PEA's anti-neuroinflammatory effects through mast cell modulation and glial control target non-cell-autonomous motor neuron toxicity in ALS.
Mechanism of Action
PEA activates PPARα nuclear receptors, downregulating NF-κB and reducing microglial and astrocytic inflammatory activation. It stabilizes mast cells, reduces pro-inflammatory cytokine release, and activates endocannabinoid signaling for neuronal protection without psychoactive effects.
General mechanism: Endocannabinoid-like lipid. PPARα agonist, mast cell stabilizer, NF-κB inhibitor, neuroinflammation modulator.
Current Evidence
ALS pilot studies show trends toward slowed decline with PEA supplementation. Anti-neuroinflammatory mechanism well-characterized. Several European studies support neurological applications.
Clinical Status: Pilot studies for ALS. Established use for chronic pain in Europe.
Safety Profile
Excellent safety. No psychoactive effects. No significant drug interactions. Micronized form improves absorption.
Key Research Questions
- Can PEA reduce neuroinflammatory biomarkers in ALS CSF?
- Does PEA combination with riluzole provide additive neuroprotection?